Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Рак полости носа и придаточных пазух

Список литературы

  1. Каприн А.Д., Старинский В.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность) – М.: МНИОИ им. П.А. Герцена филиал ФГБУ «НМИРЦ» Минздрава России, 2017., с.11, 15, 16
  2. Давыдов М.И. Энциклопедия клинической онкологии Москва, ООО «РЛС-2004», 2004
  3. Teymoortash, A. Current advanced in diagnosis and surgical treatment of lymph node metastasis in head and neck cancer / A. Teymoortash, J.A. Werner // GMS Curr. Top Otorhinolaryngol. Head Neck Surg. — 2012. — Vol. 11. — P. 04.
  4. Soo KC, Tan EH, Wee J, Lim D, Tai BC, Khoo ML, et al.: Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer 2005; 93: 279–86.
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Head and Neck Cancers. Version 2.2023
  6. Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al.: Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51: 571–8.
  7. Simmer LA, Carrau RL. Neoplasms of the nose and paranasal sinuses. Bailey BJ, Johnson JT, Newland SD, eds. Head & Neck Surgery - Otolaryngology. 4th. Lippincott, Williams & Wilkins; 2006.
  8. Caplan LS, Hall I, Levine RS, Zhu K. Preventable risk factors for nasal cancer. Ann Epidemiol. 2000. 10:186-91.
  9. Weymuller EA, Gal TJ. Neoplasms of the nasal cavity. Cummings CW, Flint PW, Harker LA et al. eds. Otolaryngology - Head and Neck surgery. 4th. Mosby; 2005.
  10. Mehanna H, Wong WL, McConkey CC, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med 2016;374:1444-1454
  11. d"Errico A, Pasian S, Baratti A, et al. A case-controlled study on occupational risk factors for sino-nasal cancer. Occup Environ Med. 2009. 66:448-55.
  12. Benninger MS. The impact of cigarette smoking and environmental tobacco smoke on nasal and sinus disease: a review of the literature. Am J Rhinol. 1999 Nov-Dec. 13(6):435-8. [Medline].
  13. _______
  14. Sasaki M, Eida S, Sumi M, Nakamura T. Apparent diffusion coefficient mapping for sinonasal diseases: differentiation of benign and malignant lesions. AJNR Am J Neuroradiol. 2011 Jun. 32(6):1100-6. [Medline].
  15. Snyderman CH, Carrau RL, deVries EJ. Johnson JT, Derkay CS, Mandell-Brown MK, Newman RK eds. Carotid artery resection: update on preoperative evaluation. Mosby; 1993. 6: 341-4.
  16. Zenda S, Kohno R, Kawashima M, et al. Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys 2011;81:1473-1478.
  17. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98
  18. Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32:2940-2950.
  19. Geoffrois L, Martin L, De Raucourt D, et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase III randomized trial. J Clin Oncol 2018;36:3077- 3083
  20. Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393:156-167
  21. Soldatova L, Campbell RG, Carrau RL, et al. Sinonasal carcinomas with neuroendocrine features: histopathological differentiation and treatment outcomes. J Neurol Surg B Skull Base 2016;77:456-465
  22. Hanna EYN, Westfall C. Cancer of the nasal cavity, paranasal sinuses and orbit. Myers EN, Suen JY, Myers JN, Hanna EYN, eds. Cancer of the head and neck. 4th. Saunders; 2003.
  23. Barnes L. Surgical pathology of the head and neck. 2nd. Marcel Dekker; 2001.
  24. Kida A, Endo S, Iida H, et al. Clinical assessment of squamous cell carcinoma of the nasal cavity proper. Auris Nasus Larynx. 1995. 22(3):172-7. [Medline].
  25. Heffner DK, Hyams VJ, Hauck KW, Lingeman C. Low-grade adenocarcinoma of the nasal cavity and paranasal sinuses. Cancer. 1982 Jul 15. 50(2):312-22. [Medline].
  26. Van Gerven L, Jorissen M, Nuyts S, Hermans R, Vander Poorten V. Long-term followup of 44 patients with adenocarcinoma of the nasal cavity and sinuses primarily treated with endoscopic resection followed by radiotherapy. Head Neck. 2011 Jun. 33(6):898904. [Medline].
  27. Claus F, Boterberg T, Ost P, et al. Postoperative radiotherapy for adenocarcinoma of the ethmoid sinuses: treatment results for 47 patients. Int J Radiat Oncol Biol Phys. 2002 Nov 15. 54(4):1089-94. [Medline].
  28. Lund VJ, Chisholm EJ, Takes RP, et al. Evidence for treatment strategies in sinonasal adenocarcinoma. Head Neck. 2012 Aug. 34(8):1168-78. [Medline].
  29. Knegt PP, Ah-See KW, vd Velden LA, Kerrebijn J. Adenocarcinoma of the ethmoidal sinus complex: surgical debulking and topical fluorouracil may be the optimal treatment. Arch Otolaryngol Head Neck Surg. 2001 Feb. 127(2):141-6. [Medline].
  30. Almeyda R, Capper J. Is surgical debridement and topical 5 fluorouracil the optimum treatment for woodworkers" adenocarcinoma of the ethmoid sinuses? A case-controlled study of a 20-year experience. Clin Otolaryngol. 2008 Oct. 33(5):435-41. [Medline].
  31. Rhee CS, Won TB, Lee CH, et al. Adenoid cystic carcinoma of the sinonasal tract: treatment results. Laryngoscope. 2006 Jun. 116(6):982-6. [Medline].
  32. Lupinetti AD, Roberts DB, Williams MD, et al. Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience. Cancer. 2007 Dec 15. 110(12):2726-31. [Medline].
  33. Szanto PA, Luna MA, Tortoledo ME, White RA. Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer. 1984 Sep 15. 54(6):1062-9. [Medline].
  34. Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg. 1997 Nov. 174(5):495-8. [Medline].
  35. Frierson HF Jr, Mills SE, Fechner RE, Taxy JB, Levine PA. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol. 1986 Nov. 10(11):771-9. [Medline].
  36. Enepekides DJ. Sinonasal undifferentiated carcinoma: an update. Curr Opin Otolaryngol Head Neck Surg. 2005 Aug. 13(4):222-5. [Medline].
  37. Cerilli LA, Holst VA, Brandwein MS, Stoler MH, Mills SE. Sinonasal undifferentiated carcinoma: immunohistochemical profile and lack of EBV association. Am J Surg Pathol. 2001 Feb. 25(2):156-63. [Medline].
  38. Mendenhall WM, Mendenhall CM, Riggs CE Jr, Villaret DB, Mendenhall NP. Sinonasal undifferentiated carcinoma. Am J Clin Oncol. 2006 Feb. 29(1):27-31. [Medline].
  39. Hyams VJ. Olfactory neuroblastoma (case 6). Batsakis JG, Hyams VJ, Morales AR, eds. Specifial tumors of the head and neck. Chicago: American Society of Clinical Pathologist Press; 1992. 24-29.
  40. Malouf GG, Casiraghi O, Deutsch E, Guigay J, Temam S, Bourhis J. Low- and highgrade esthesioneuroblastomas display a distinct natural history and outcome. Eur J Cancer. 2013 Apr. 49(6):1324-34. [Medline].
  41. Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope. 1992 Aug. 102(8):843-9. [Medline].
  42. Folbe A, Herzallah I, Duvvuri U, et al. Endoscopic endonasal resection of esthesioneuroblastoma: a multicenter study. Am J Rhinol Allergy. 2009 Jan-Feb. 23(1):91-4. [Medline].
  43. Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients. Laryngoscope. 2009 Jul. 119(7):1412-6. [Medline].
  44. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001 Nov. 2(11):683-90. [Medline].
  45. Loy AH, Reibel JF, Read PW, et al. Esthesioneuroblastoma: continued follow-up of a single institution"s experience. Arch Otolaryngol Head Neck Surg. 2006 Feb. 132(2):134-8. [Medline].
  46. Patil VM, Joshi A, Noronha V, et al. Neoadjuvant chemotherapy in locally advanced and borderline resectable nonsquamous sinonasal tumors (esthesioneuroblastoma and sinonasal tumor with neuroendocrinedifferentiation). Int J Surg Oncol 2016;2016:6923730
  47. Lewis JE, Rohlinger AL, Weaver AL, Olsen KD. Sinonasal melanoma: a clinicopathologic review of 61 cases. Otolaryngol Head Neck Surg. 2008 Mar. 138(3):347-52. [Medline].
  48. Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Villaret DB, Mendenhall NP. Head and neck mucosal melanoma. Am J Clin Oncol. 2005 Dec. 28(6):626-30. [Medline].
  49. Resto VA, Eisele DW, Forastiere A, et al. Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck 2000;22:550-558.
  50. Wagner M, Morris CG, Werning JW, Mendenhall WM. Mucosal melanoma of the head and neck. Am J Clin Oncol. 2008 Feb. 31(1):43-8. [Medline].
  51. Hillstrom RP, Zarbo RJ, Jacobs JR. Nerve sheath tumors of the paranasal sinuses: electron microscopy and histopathologic diagnosis. Otolaryngol Head Neck Surg. 1990 Mar. 102(3):257-63. [Medline].
  52. Greene FL, Page DL, Fleming ID, et al. eds. Nasal cavity and paranasalsinues. AJCC Cancer Staging Manual. New York: Springer - Verlga; 2002. 6: 59-67.
  53. Hojo H, Zenda S, Akimoto T, et al. Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies. J Radiat Res. 2012 Sep. 53(5):704-9. [Medline]. [Full Text].
  54. Swegal W, Koyfman S, Scharpf J, et al. Endoscopic and open surgical approaches to locally advanced sinonasal melanoma: comparing the therapeutic benefits. JAMA Otolaryngol Head Neck Surg. 2014 Sep. 140 (9):840-5. [Medline].
  55. Hadad G, Bassagasteguy L, Carrau RL, et al. A novel reconstructive technique after endoscopic expanded endonasal approaches: vascular pedicle nasoseptal flap. Laryngoscope. 2006 Oct. 116(10):1882-6. [Medline].
  56. Nicolai P, Battaglia P, Bignami M, et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol. 2008 MayJun. 22(3):308-16. [Medline].
  57. Резолюция экспертного совета по вопросу о роли цетуксимаба в лечении пациентов с плоскоклеточным раком головы и шеи. Опухоли головы и шеи 2019; 8: 71–3.
  58. Wu Q, Mohan R, Morris M, et al. Simultaneous integrated boost intensitymodulated radiotherapy for locally advanced head-and-neck squamous cell
  59. carcinomas. I: dosimetric results. Int J Radiat Oncol Biol Phys 2003;56:573-585 .
  60. Стандарты лучевой терапии. Под ред. А.Д. Каприна, А.А. Костина, Е.В. Хмелевского. М.: ГЭОТАР-Медиа, 2019. С. 15–35.
  61. Hoppe BS, Stegman LD, Zelefsky MJ, et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience. Int J Radiat Oncol Biol Phys. 2007 Mar 1. 67(3):691-702. [Medline].
  62. Daly ME, Chen AM, Bucci MK, et al. Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. 2007 Jan 1. 67(1):151-7. [Medline].
  63. Patel SG, Singh B, Polluri A, et al. Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer. 2003 Sep 15. 98(6):1179-87. [Medline].
  64. Suarez C, Ferlito A, Lund VJ, et al. Management of the orbit in malignant sinonasal tumors. Head Neck. 2008 Feb. 30(2):242-50. [Medline].
  65. Self EM, Bumpous J, Ziegler C, Wilson L, Potts K. Risk factors for hemorrhage after chemoradiation for oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2013 Apr;139(4):356-61. doi: 10.1001/jamaoto.2013.103. PMID: 23599070.
  66. TaunkNK, HafftyBG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. 2015 Feb 18;5:39. doi: 10.3389/fonc.2015.00039. PMID: 25741474; PMCID: PMC4332338.(Self EM, Bumpous J, Ziegler C, Wilson L, Potts K. Risk factors for hemorrhage after chemoradiation for oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2013 Apr;139(4):356-61. doi: 10.1001/jamaoto.2013.103. PMID: 23599070.)
  67. Sittel C, Gossmann A, Jungehu¨lsing M, Za¨hringer M. Superselective embolization as palliative treatment of recurrent hemorrhage in advanced carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 2001;110(12):1126-1128.
  68. Kumra V, Vastola AP, Keiserman S, Lucente FE. Spontaneous tonsillar hemorrhage. Otolaryngol Head Neck Surg. 2001;124(1):51-52.
  69. Smith TP. Embolization in the external carotid artery. J VascIntervRadiol. 2006 Dec;17(12):1897-912; quiz 1913. doi: 10.1097/01.RVI.0000247301.64269.27. PMID: 17185685.
  70. Kumar T, Yadav V, Ravi K, Ramaswamy K, Patel MH, Kothari K. External Carotid Artery Ligation in Squamous Cell Carcinomas of the Oral Cavity and Oropharynx: an Oncological Emergency. Indian J Surg. 2015 Dec;77(Suppl 3):850-2. doi: 10.1007/s12262-014-1035-4. Epub2014 Jan 23. PMID: 27011469; PMCID: PMC4775627.
  71. Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an openlabel phase 3 randomised trial. Lancet Oncol 2012;13:145-153.
  72. Beckmann GK, Hoppe F, Pfreundner L, Flentje MP. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck  2005;27:36-43.
  73. Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent  chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone  in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013;14:257-264.
  74. Stevens CM, Huang SH, Fung S, et al. Retrospective study of palliative radiotherapy in newly diagnosed head and neck carcinoma. Int J Radiat Oncol Biol Phys 2011;81:958-963
  75. Porceddu SV, Rosser B, Burmeister BH, et al. Hypofractioned radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment-“Hypo Trial.” Radiother Oncol 2007;85:456-462.
  76. Болотина Л. В., Владимирова Л. Ю., Деньгина Н. В., Новик А. В., Романов И. С. Практические рекомендации по лечению злокачественных опухолей головы и шеи // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 71–82.
  77. Guigay J, Fayette J, Dillies A-F, et al. Cetuximab, docetaxel, and cisplatin (TPEx) as first-line  treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and  neck (SCCHN): Final results of phase II trial GORTEC 2008-03 [abstract]. J Clin Oncol 2012;30(suppl  15):Abstract 5505.
  78. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-5587.
  79. Leeann Geraghty Thomas E. Schultz Sarah E. Hoffman Kyle Porter Majd Issa Vidhya Karivedu Marcelo Bonomi Weekly vs. 3‑weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer MOLECULAR AND CLINICAL ONCOLOGY 15: 240, 2021.
  80. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567.
  81. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-1251
  82. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76.
  83. ________
  84. Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest. 2007;25:182-188
  85. Adeline Pêtre, Cécile Dalban, Andy Karabajakian, Eve-Marie Neidhardt, Pierre Eric Roux, Marc Poupart, Sophie Deneuve, Philippe Zrounba and Jérome Fayette. Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule. Oncotarget. 2018 Apr 24; 9(31): 22038–22046. doi: 10.18632/oncotarget.25157.
  86. Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest 2007;25:182-188.
  87. L. Specht, S. Kornum Larsen2, H. Sand Hansen Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Annals of Oncology 11: 845-849, 2000.
  88. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394:1915-1928.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*